ArticleHaematologica2017
Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome.
Article in Haematologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 58 citations in OpenAlex.
- Red cell autoimmunization and alloimmunization in myelodysplastic syndromes: prevalence, characteristic and significance.Haematologica · 2019Trial
- Optimization of the antibody identification interval in a high-volume transfusion centre.Vox sanguinis · 2026Article
- The true cost of red cell transfusion for patients with myelodysplastic syndromes: A time-driven activity-based costing study.British journal of haematology · 2026Article
- The Incidence of Hemolytic and Serologic Transfusion Reactions Among Patients with Hematological Malignancies at Mbarara Regional Referral Hospital and the Uganda Cancer Institute, in Uganda.Journal of blood medicine · 2026Article
- Article
- Article
- A clinical effect of disease-modifying treatment on alloimmunisation in transfused patients with myelodysplastic syndromes: data from a population-based study.Blood transfusion = Trasfusione del sangue · 2022Observational
- Generation of 'designer erythroblasts' lacking one or more blood group systems from CRISPR/Cas9 gene-edited human-induced pluripotent stem cells.Journal of cellular and molecular medicine · 2021Article
- [Life-threatening hyperkalemia due to a delayed hemolytic transfusion reaction].Zeitschrift fur Gerontologie und Geriatrie · 2021Article
- Antigen density dictates RBC clearance, but not antigen modulation, following incompatible RBC transfusion in mice.Blood advances · 2021Article
- Outpatient transfusions for myelodysplastic syndromes.Hematology. American Society of Hematology. Education Program · 2020Review
- Red blood cell alloimmunization and sickle cell disease: a narrative review on antibody induction.Annals of blood · 2020Article
- Prevalence of Red Blood Cell Alloimmunization among Transfused Chronic Kidney Disease Patients in Hospital Universiti Sains Malaysia.Oman medical journal · 2020Article
- Treatment of Anemia in Transfusion-Dependent and Non-Transfusion-Dependent Lower-Risk MDS: Current and Emerging Strategies.HemaSphere · 2019Review
- Examining the Role of Complement in Predicting, Preventing, and Treating Hemolytic Transfusion Reactions.Transfusion medicine reviews · 2019Review
- Type 1 IFN signaling critically regulates influenza-induced alloimmunization to transfused KEL RBCs in a murine model.Transfusion · 2019Article
- Challenges in preventing and treating hemolytic complications associated with red blood cell transfusion.Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine · 2019Review
- Review
- Red Blood Cell Alloimmunization in Korean Patients With Myelodysplastic Syndrome and Liver Cirrhosis.Annals of laboratory medicine · 2019Article
- Rhesus pieces: genotype matching of RBCs.Blood · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Up to 90% of patients with a myelodysplastic syndrome require red blood cell transfusion; nevertheless, comprehensive data on red cell alloimmunization in such patients are limited. This study evaluates the incidence and clinical impact of red cell alloimmunization in a large cohort of patients with myelodysplastic syndrome registered in the statewide South Australian-MDS registry. The median age of the 817 patients studied was 73 years, and 66% were male. The cumulative incidence of alloimmunization was 11%. Disease-modifying therapy was associated with a lower risk of alloimmunization while alloimmunization was significantly higher in patients with a revised International Prognostic Scoring System classification of Very Low, Low or Intermediate risk compared to those with a High or Very High risk (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.